Inspired by the wealth of nature - the venom of tropical sea snails

we have created a unique cosmeceutical, Miorelaxant Magic.

The secret of Miorelaxant Magic is a unique, globally exclusive ingredient with myorelaxant properties, meaning it relaxes facial mimic muscles, obtained through biotechnological methods in a laboratory.

The cream's production process utilized the latest technological advancements – cosmetic product tests were conducted on a skin model, and application tests were performed on a group of volunteers.

A revolution in daily skincare with the strongest possible anti-wrinkle action, enriched with unique nourishing ingredients, biomimetic peptides, and an innovative skin penetration promoter.

The cosmeceutical Miorelaxant Magic is an effective, unique, yet non-invasive and safe way to achieve a younger appearance.

Recombinant proprietary conotoxin

Obtaining the expression of the gene encoding a myorelaxant conotoxin in the bacterial strain E.coli .

Our proprietary active substance - recombinant conotoxin, is obtained from E. coli bacterial strains. The conotoxin we obtain is identical to that originally produced by sea snails of the genus Conus .

Recombinant conotoxin is created as a fusion protein from recombinant genes, i.e. DNA molecules - deoxyribonucleic acid, which is the most common carrier of genetic information. Gene expression in bacterial cells is possible thanks to the use of special expression vectors with a strong promoter enabling the production of large amounts of protein in the recipient cell.

Expression imaging of the gene encoding a recombinant conotoxin

We use the gel electrophoresis technique to separate DNA fragments obtained in our laboratory based on their size and charge .

DNA molecules have a negative charge on their surface, so under the influence of an applied current they move in the agarose or polyacrylamide gel towards the positive electrode. To identify the size of DNA molecules, a mass standard is placed on the gel, which migrates in the gel in parallel with the analyzed sample and allows us to determine whether the desired product has been obtained.

By comparing the bands from the tested sample with the standard bands, we are able to determine the size of DNA molecules in the tested sample. The agarose gels with electrophoretically separated DNA fragments obtained in our laboratory are made visible thanks to a dye that binds to deoxyribonucleic acid and then glows under the influence of UV light.

Culture of an E. coli strain expressing a recomminant conotoxin

After obtaining the expression of the gene encoding the conotoxin, the breeding conditions of the host strain producing our active substance are selected. Both eukaryotic and prokaryotic expression systems are used to overproduce recombinant proteins.

Purification of recombinant conotoxin by affinity chromatography

The presence of recombinant conotoxin in cultures is confirmed on protein gels by SDS-PAGE electrophoresis, then the active substance of our cosmeceutical is purified using affinity chromatography methods. The peptide purification process is multi-stage, so we can be sure that we are getting rid of all bacterial contamination. The next step is to select the dialysis conditions in order to obtain a correctly folded peptide that has three disulfide bridges stabilizing its structure.

Confirmation of the activity of the author's recombinant conotoxin on oocyte cells

The final stage of production of the active ingredient of the Miorelaxant Magic cosmeceutical is the in vitro determination of the activity of the recombinant conotoxin and the introduction into a cream formulation that ensures the stability and activity of the conotoxin, guaranteeing its effectiveness. We confirm the conotoxin activity test using the patch-clamp method on live oocyte cell lines that overexpress human sodium channels specific for conotoxins. This study confirmed the myorelaxant activity of the recombinant conotoxin we obtained.

Klinicznie udowodnione Clinically proven

Nauka, której nie da się podważyć Science you can't argue with

Randomizowane badanie z podwójnym zaślepieniem i grupą placebo. 60 ochotników, 6 miesięcy obserwacji, wyniki potwierdzone przez niezależny panel ekspertów. Randomized, double-blind, placebo-controlled clinical trial. 60 volunteers, 6 months of observation, results confirmed by an independent expert panel.

+39%
lepszy efekt estetyczny
vs placebo po 6 miesiącach better aesthetic effect
vs placebo after 6 months
ocena niezależnych ekspertów independent expert evaluation
+17%
wyższa satysfakcja
w spoczynku vs placebo higher satisfaction
at rest vs placebo
samoocena pacjentów, dzień 180 patient self-assessment, day 180
+23%
wyższa satysfakcja
podczas mimiki vs placebo higher satisfaction
during facial expressions vs placebo
samoocena pacjentów, dzień 180 patient self-assessment, day 180

Efekt estetyczny w czasie — ocena niezależnych ekspertów Aesthetic effect over time — independent expert evaluation

Obie grupy otrzymały zabieg z toksyną botulinową. Następnie przez 6 miesięcy stosowały krem — jedna z konotoksyną, druga bez (placebo). Od dnia 90. różnica rośnie na korzyść konotoksyny. Both groups received a botulinum toxin treatment. Then for 6 months they used a cream — one with conotoxin, the other without (placebo). From day 90, the difference grows in favor of conotoxin.

Miorelaxant Magic™ z konotoksyną Miorelaxant Magic™ with conotoxin
Placebo (krem bez konotoksyny) Placebo (cream without conotoxin)
5.0 4.0 3.0 2.0 1.0 30 60 90 105 120 135 150 165 180 dni od zabiegu days after treatment p < 0.05 — istotność statystyczna p < 0.05 — statistical significance 3.28 2.36 +39%

Różnice statystycznie istotne (p<0.05) od dnia 90. W dniu 180 p≈0.0000 — najwyższa istotność. Skala 1–5, ocena efektu estetycznego przez niezależny panel ekspertów na podstawie medycznej dokumentacji fotograficznej. Statistically significant differences (p<0.05) from day 90. At day 180, p≈0.0000 — highest significance. Scale 1–5, aesthetic effect evaluation by an independent expert panel based on medical photographic documentation.

test t-Studenta, p<0.001 od dnia 135 Student's t-test, p<0.001 from day 135

Efekty konotoksyny Conotoxin effects

Wspomaganie efektu zabiegu Treatment effect support +39%

vs placebo, ocena ekspertów, 180 dni vs placebo, expert evaluation, 180 days

Kontrola łojotoku Sebum control 3.8/5

istotne od dnia 105, brak efektu w placebo significant from day 105, no effect in placebo

Poprawa kolorytu skóry Skin tone improvement p=0.005

istotne od dnia 60, brak efektu w placebo significant from day 60, no effect in placebo

Efekty bazy kremowej Cream base effects

Nawilżenie skóry Skin hydration +16%

pomiary kutometryczne, obie grupy, 180 dni corneometer measurements, both groups, 180 days

Elastyczność skóry Skin elasticity +8.8%

pomiary kutometryczne, 180 dni, p<0.001 corneometer measurements, 180 days, p<0.001

Satysfakcja z elastyczności Elasticity satisfaction 4.1/5

obie grupy porównywalnie — efekt bazy both groups comparable — base formula effect

Profil bezpieczeństwa >95% Safety profile >95%

Reakcje skórne u mniej niż 5% uczestników, przypisane iniekcji toksyny botulinowej. Objawy uboczne (swędzenie, pieczenie, zdrętwienie) występowały częściej w grupie placebo niż w grupie stosującej krem z konotoksyną. Skin reactions in fewer than 5% of participants, attributed to the botulinum toxin injection. Side effects (itching, burning, numbness) occurred more frequently in the placebo group than in the conotoxin cream group.

Badanie: K-LAB Badania i Rozwój, Gdynia · Standard ISO 14155:2020 · Główny badacz: dr n. med. Paweł Kubik · 60 ochotników (30+30), wiek 30–68 lat · Randomizacja + podwójne zaślepienie · Toksyna botulinowa 20j. + krem 2×/dziennie przez 180 dni · Pomiary: kutometr Multi Skin Test Centre 1000, dokumentacja foto FotoMedicus · Pozytywna opinia Komisji Bioetycznej przy OIL w Gdańsku · REP/1/4/S4B/K-LAB/2023/PL Study: K-LAB Research & Development, Gdynia, Poland · ISO 14155:2020 standard · Principal investigator: Paweł Kubik, MD, PhD · 60 volunteers (30+30), age 30–68 · Randomized + double-blinded · Botulinum toxin 20u + cream 2×/day for 180 days · Measurements: corneometer Multi Skin Test Centre 1000, FotoMedicus photo documentation · Bioethics Committee approval, Gdańsk · REP/1/4/S4B/K-LAB/2023/PL

Pełny raport z badania klinicznego Full clinical study report

173 strony · metodologia, wyniki, analiza statystyczna 173 pages · methodology, results, statistical analysis

Pobierz PDF Download PDF

BEFORE AND AFTER

Results of application tests after 28 days of using Miorelaxant Magic cream twice a day by a group of 60 volunteers.

Check the results after 28 days:

  • Improved skin condition:


    Good hydration: 80%

    Increased skin softness: 71%

    Increased skin tension: 71%

    Increased skin brightness: 58%

    Reduction of the visibility of wrinkles: 42%

    Uniform color: 42%

    Reduction of the visibility of pores: 42%

    Reduction of sebum secretion: 47%

    Button label

  • Reduced and shortened wrinkles


    Reduced wrinkle depth: 42%

    Reduced wrinkle length: 36%

    Reduced number of wrinkles: 32%

    Suitable consistency: 95%

    Adequate absorption: 87%

    Suitable color: 96%

    Ease of application: 93%

    Noticeable difference in skin condition: 65%

    Button label

  • Product safety test reports


    1. Skin irritation test

    2. Corneal irritation test

    3. Phototoxicity

    Button label